7:00 PM - 7:05 PM Welcome and Introduction
7:05 PM - 7:15 PM DNA Damage Repair Genes: Prevalence and Impact on Prognosis – Celestia S. Higano, MD
7:15 PM - 7:40 PM Practical Guidance on the Assessment of BRCA and Other DNA Damage Repair Genes in Prostate Cancer – Celestia S. Higano, MD, FACP
7:40 PM - 8:10 PM Targeting DNA Repair Defects in Prostate Cancer: The Role of PARP Inhibitors – Charles J. Ryan, MD
8:10 PM - 8:25 PM Case Discussions: Applying the Data to Practice—Therapeutic Planning for Patients With DRG Defects (BRCA1/2 or ATM Mutations) – Celestia S. Higano, MD, FACP (lead moderator), and Charles J. Ryan, MD
8:25 PM - 8:30 PM Final Faculty Comments and Audience Question and Answer Session – Celestia S. Higano, MD, FACP (lead moderator), and Charles J. Ryan, MD
Date / Time
Celestia S. Higano, MD
Departments of Medicine and Urology
University of Washington
Charles J. Ryan, MD
Professor of Medicine
B.J. Kennedy Chair in Clinical Medical Oncology
Director, Division of Hematology, Oncology and Transplantation
Department of Medicine
University of Minnesota
Division of Hematology, Oncology and Transplantation
University of Minnesota Health Clinics and Surgery Center
The goal of this activity is to improve the knowledge, confidence, and competence of learners to integrate PARP inhibitors into the treatment of men with prostate cancer.
This program is intended for physicians and other healthcare providers who care for patients with prostate cancer.
- Describe the rationale and process for assessing germline and somatic DNA repair pathway alterations in prostate cancer including the poor prognosis in the absence of targeted treatment
- Examine the mechanism of PARP inhibition to achieve “synthetic lethality” in prostate cancer with deficient DNA damage response
- Interpret test results for predictive markers of PARP inhibitor benefit following evaluation of the available clinical evidence in CRPC harboring BRCA1/2 or other DNA damage response mutations
- Select PARP inhibitor treatment for appropriate men with prostate cancer
- Manage adverse events and other barriers to adherence from PARP inhibitors
- Identify patients suitable for enrollment on ongoing clinical studies investigating PARP inhibitor monotherapy or in combination with other agents in prostate cancer
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.